VB6-845 is a recombinant immunotoxin comprised of deBouganin (a de-immunized plant toxin) genetically linked to an epithelial cell adhesion molecule (EpCAM)-targeting humanized Fab fragment (4D5MOCB). EpCAM is highly expressed on a wide range of epithelial tumors but has limited expression on most normal epithelia and therefore represents an excellent target for immunotherapy. A comprehensive preclinical evaluation was performed to determine the safety and suitability of VB6-845 as a systemically administered drug for the treatment of solid tumors. Efficacy studies in mice demonstrated that VB6-845 specifically and potently targeted EpCAM-positive tumors. In a dose-ranging study in Sprague–Dawley rats, single doses of VB6-845 were well-tolerated resulting in a no-observable adverse effect level (NOAEL) of 100 mg/kg whereas repeated doses of VB6-845 resulted in vascular leak-associated symptoms particularly at higher dose levels. However, much higher doses in Cynomolgus monkeys were well-tolerated when given as a 3-hour infusion mimicking the intended route of administration in the clinic. In addition, VB6-845 proved to be minimally immunogenic in monkeys. The toxicological data obtained in Cynomolgus monkeys indicated an excellent safety profile with a NOAEL value of 30 mg/kg (equivalent to a 10 mg/kg dose in humans). These results are supportive of an exploratory Phase I trial.
Get full access to this article
View all access options for this article.
References
1.
ReiterY. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res, 2001; 81:93.
2.
StirpeF, BattelliMG. Ribosome-inactivating proteins: Progress and problems. Cell Mol Life Sci, 2006; 63:1850.
3.
PastanI, HassanR, FitzGeraldDJet al.Immunotoxin treatment of cancer. Annu Rev Med, 2007; 58:221.
4.
FabbriA, TravaglioneS, FalzanoLet al.Bacterial protein toxins: Current and potential clinical use. Curr Med Chem, 2008; 15:1116.
5.
PennellCA, EricksonHA. Designing immunotoxins for cancer therapy. Immunol Res, 2002; 25:177.
6.
FracassoG, BellisolaG, CastellettiDet al.Immunotoxins and other conjugates: Preparation and general characteristics. Mini Rev Med Chem, 2004; 4:545.
7.
CarterPJ, SenterPD. Antibody-drug conjugates for cancer therapy. Cancer J, 2008; 14:154.
8.
WayneAS, KreitmanRJ, FindleyHWet al.Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: Preclinical studies and Phase I clinical trial. Clin Cancer Res, 2010; 16:1894.
9.
KreitmanRJ. Immunotoxins for targeted cancer therapy. AAPS J, 2006; 8:E532.
TeicherBA. Antibody-drug conjugate targets. Curr Cancer Drug Targets, 2009; 9:982.
12.
MomburgF, MoldenhauerG, HämmerlingGJet al.Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res, 1987; 47:2883.
13.
OguraE, SenzakiH, YoshizawaKet al.Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer Res, 1998; 18:3669.
14.
XieX, WangCY, CaoYXet al.Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol, 2005; 11:344.
15.
BrownJ, RasamoelisoloM, SpearmanMet al.Preclinical assessment of an anti-EpCAM immunotoxin: Locoregional delivery provides a safer alternative to systemic administration. Cancer Biother Radiopharm, 2009; 24:477.
16.
de BonoJS, TolcherAW, ForeroAet al.ING-1, a monoclonal antibody targeting Ep-CAM in patients with advance adenocarcinomas. Clin Cancer Res, 2004; 10:7555.
17.
RufP, GiresO, JägerMet al.Characterisation of the new EpCAM-specific antibody HO-3: Implications for trifunctional antibody immunotherapy of cancer. Br J Cancer, 2007; 97:315.
18.
BrischweinK, SchlerethB, GullerBet al.MT110: A novel bispecific single-chain antibody construct with thigh efficacy in eradicating established tumors. Mol Immunol, 2006; 43:1129.
19.
KirmanI, WhelanRL. Drug evaluation: Adecatumumab, an engineered human anti-EpCAM antibody. Curr Opin Mol Ther, 2007; 9:190.
20.
GoelS, BauerRJ, DesaiKet al.Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Ann Oncol, 2007; 18:1704.
21.
FrankelAE. Reducing the immune response to immuntotoxin. Commentary re R. Hassan et al., Pretreatment with Rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res, 2004; 10:13.
22.
BolognesiA, PolitoL. Immunotoxins and other conjugates: Pre-clinical studies. Mini-Rev Med Chem, 2004; 4:563.
23.
MacDonaldGC, GloverN. Effective tumor targeting: Strategies for the delivery of armed antibodies. Curr Opin Drug Discov Devel, 2005; 8:177.
24.
LiZ, YuT, ZhaoPet al.Immunotoxins and cancer therapy. Cell Mol Immunol, 2005; 2:106.
25.
GouldBJ, BorowitzMJ, GrovesESet al.Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst, 1989; 81:775.
26.
BrinkmannU, Keppler-HafkemeyerA, HafkemeyerP. Recombinant immunotoxins for cancer therapy. Expert Opin Biol Ther, 2001; 1:693.
27.
SmallshawJE, GhetieV, RizoJet al.Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol, 2003; 21:387.
28.
MacDonaldGC, RasamoelisoloM, EntwistleJet al.A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Dev Ther, 2008; 2:105.
29.
MacDonaldGC, RasamoelisoloM, EntwistleJet al.A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck. Med Oncol, 2009; 26:257.
30.
KowalskiM, EntwistleJ, CizeauJet al.A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of non muscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des Devel Ther, 2010; 4:313.
31.
CizeauJ, GrenkowDM, BrownJGet al.Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of hte plant toxin bouganin. J Immunother, 2009; 32:574.
32.
BolognesiA, PolitoL, OlivieriFet al.New ribosome-inactivating proteins with polynucleotide:adenosine glycosidase and antiviral activities from Basella rubra L. and Bougainvillea spectabilis Willd. Planta, 1997; 203:422.
33.
den HartogMT, LubelliC, BoonLet al.Cloning and expression of cDNA coding for bouganin. Eur J Biochem, 2002; 269:1772.
34.
BolognesiA, PolitoL, TazzariPLet al.In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type I ribosome-inactivating proteins. Br J Haematol, 2000; 110:351.
35.
Food and Drug Administration (FDA). Guidance for Submission of Immunohistochemistry Applications to the FDA. Final Guidance for Industry, 1998. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094002.htm. 2011 December 7.
36.
BalzarM, WinterMJ, de BoerCJet al.The biology of the 17-1A antigen (Ep-CAM)J Mol Med, 1999; 77:699.
37.
WinterMJ, NagtegaalID, HanJet al.The Epithelial Cell Adhesion Molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol, 2003; 163:2139.
38.
WentPT, LugliA, MeierSet al.Frequent EpCAM protein expression in human carcinomas. Hum Pathol, 2004; 35:122.
39.
WentP, DirnhoferS, SchöpfDet al.Expression and prognostic significance of EpCAM. J Cancer Mol, 2008; 3:169.
40.
LevineS, SaltzmanA. Distribution of small intestinal lesions in anaphylaxis of rats. Int. Arch Allergy Immunol, 1998; 115:312.
FrankelAE, KreitmanRJ, SausvilleEA. Targeted toxins. Clin Cancer Res, 2000; 6:326.
43.
VitettaES. Immunotoxins and vascular leak syndrome. Cancer J, 2000; 6:S218.
44.
TsutsumiY, OndaM, NagataSet al.Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci U S A, 2000; 97:8548.
45.
FilpulaD, YangK, BasuAet al.Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem, 2007; 18:773.
46.
SelvaggiK, SariaEA, SchwartzRet al.Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol, 1993; 13:201.
47.
OndaM, NagataS, FitzGeraldDJet al.Characterization of the B cell epitopes associated with a truncated from of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol, 2006; 177:8822.
48.
OndaM. Reducing the immunogenicity of protein therapeutics. Curr Drug Targets, 2009; 10:131.
49.
MathewM, VermaRS. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci, 2009; 100:1359.
50.
LitvinovSV, van DrielW, van RhijnCMet al.Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol, 1996; 148:865.
51.
RalhanR, CaoJ, LimTet al.EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer, 2010; 10:331.
52.
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. http://www.fda.gov/cder/guidance/index.htm. 2010 January 5.
53.
SiegallCB, LiggettD, ChaceDet al.Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxin and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res, 1997; 3:339.
WithersGD, KubesP, IbbotsonGet al.Anaphylaxis-induced mesenteric vascular permeability, granulocyte adhesion, and platelet aggregates in rat. Am J Physiol Heart Circ Physiol, 1998; 275:H274.
56.
FeitosaRFG, MelciadesGB, AssreuyAMSet al.The pharmacological profile of ovalbumin-induced paw oedema in rats. Mediators Inflamm, 2002; 11:155.
57.
BattelliMG, BuonamiciL, PolitoLet al.Hepatotoxicity of ricin, saporin or a saporin immunotoxin: Xanthine oxidase activity in rat liver and blood serum. Virchows Arch, 1996; 427:529.
58.
SiegallCB, LiggittD, ChaceDet al.Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci U S A, 1994; 91:9514.
59.
HolligerP, HudsonPJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol, 2005; 23:1126.
60.
ReimannKA, TurnerS, LambertJMet al.In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Transplantation, 1989; 48:906.
61.
Food and Drug Administration (FDA). Estimating the safe starting dose in clinical trial for therapeutics in adult healthy volunteers. 2005; 5–7. CDER: Rockville, MD
62.
Food and Drug Administration (FDA). General guide for starting dose selection for a cytotoxic agent in cancer patients. 2006. www.fda.gov/cder/cancer/docs/doseflow.pdf. 2011 December 7.
63.
Charles River. Baseline Haematology and Clinical Chemistry Values for Charles River CD®[Crl:CD®(SD)BR] Rats as a Function of Sex and Age. Charles River Technical Bulletin, 1984Montreal, PQ.
64.
LillieLE, TempleNJ, FlorenceLZ. Reference values for young normal Sprague-Dawley rats: Weight gain, hematology and clinical chemistry. Hum Exp Toxicol, 1996; 15:612.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
